Endocare Comments on Unsolicite... ( IRVINE Calif. Aug. 7 /- The Board...)

Endocare Comments on Unsolicited Proposal

Date:8/7/2008

IRVINE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- The Board of Directors of Endocare, Inc. (Nasdaq: ENDO) received on August 6, 2008 an unsolicited proposal from HealthTronics, Inc. (Nasdaq: HTRN) to purchase all of the outstanding shares of Endocare common stock for $2.28 per share in cash.

Endocare's Board of Directors, consistent with its fiduciary duties, and in consultation with its financial and legal advisors, will review and consider HealthTronics' unsolicited proposal carefully and promptly in the context of Endocare's strategic plans and pursue the best course of action for the long-term value to stockholders.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Investor Contact: Media Contact: For Additional Information:

Matt Clawson Len Hall Craig T. Davenport, CEO

Allen & Caron, Inc. Allen & Caron, Inc. Michael R. Rodriguez, CFO

(949) 474-4300 (949) 474-4300 Endocare, Inc.
'/>"/>

1

GOOD

Page: 1 2
Related medicine news :

1. Endocare Stock to Commence Trading on NASDAQ
2. Endocare Reports 2007 Third Quarter and Nine-Month Results
3. Endocare Announces That National Cancer Institute to Sponsor Study Comparing Cryoablation to Radiation Therapy for Pain Relief in Bone Cancer Patients
4. Endocare Reports 2007 Annual and Fourth Quarter Financial Results
5. Endocare to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
6. Endocare Reports Financial Results for Second Quarter 2008
7. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
8. QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million
9. The Branded Pharmaceutical Association Comments on Hydrocodone
10. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
11. Pelosi Statement on Stark Comments

Post Your Comments:

Endocare Comments on Unsolicite...( IRVINE Calif. Aug. 7 /- The Board...),Health